GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Goldman Sachs Alternatives buys control of Italian medtech firm Numantec - Finance news and analysis from Global Banking & Finance Review
Finance

Goldman Sachs Alternatives buys control of Italian medtech firm Numantec

Published by Global Banking & Finance Review

Posted on July 27, 2026

2 min read

· Last updated: July 27, 2026

Add as preferred source on Google

Goldman Sachs Buys Control of Italian Medtech Firm Numantec from White Bridge

Goldman Sachs Acquisition of Numantec: Key Details and Implications

Overview of the Acquisition

MILAN, July 27 (Reuters) - The private equity arm of Goldman Sachs has agreed to acquire control of Italian medical equipment maker Numantec from White Bridge Investment, the companies said, betting on a business with steady revenues amid macroeconomic uncertainty.

About Numantec

Company Profile

Based near the northern Italian city of Mantua, Numantec supplies a range of healthcare products and drug-delivery devices. The company employs about 600 people and operates seven manufacturing facilities across Europe and the United States.

Growth Through Acquisitions

White Bridge built Numantec through a string of acquisitions after a 2021 investment in Delta Med, an Italian manufacturer of high-quality vascular access devices. 

Deal Financials and Valuation

Financial Details

    The companies provided no financials details of the deal.

Estimated Valuation

A person with knowledge of the matter told Reuters the sale valued Numantec at around €700 million.

Future Plans and Market Expansion

Expansion Strategy

Under its new owners, the person said, the company is expected to continue expanding in Europe and strengthening its presence in the United States, a market it entered last year when it bought rival Health Line International.

Transaction Timeline

The transaction is expected to close in the fourth quarter.

Advisers Involved in the Deal

White Bridge Advisers

JPMorgan acted as financial adviser to White Bridge. 

Goldman Sachs Advisers

Goldman Sachs International advised Goldman Sachs Alternatives, the U.S. bank's business that includes its private equity activities.

Reporting and Editing

(Reporting by Elvira Pollina; Editing by Valentina Za)

Key Takeaways

  • Numantec, based near Mantua with ~600 employees and seven plants across Europe and the U.S., was built via White Bridge’s buy‑and‑build strategy, including acquisitions like Delta Med (2021), Health Line (2025), PHS Medical (2024), Saflo™ rights (2024), and DualCap® (2026) (numantecgroup.com).
  • Deal valuation is estimated around €700 million and reflects interest from major private equity players amid macro uncertainty; Numantec’s revenues are around €200 million (aifi.it).
  • Goldman Sachs Alternatives plans to support continued expansion in Europe and the U.S.—building on Numantec’s recent U.S. entry via Health Line and DualCap® acquisitions; transaction expected to close in Q4 2026 with JPMorgan advising seller and Goldman Sachs International advising buyer (aifi.it).

References

Frequently Asked Questions

Who acquired Numantec?
The private equity arm of Goldman Sachs, known as Goldman Sachs Alternatives, acquired control of Numantec.
Who was the previous owner of Numantec?
White Bridge Investment was the previous owner of Numantec.
What is the estimated value of the Numantec deal?
The sale valued Numantec at around €700 million, according to a person with knowledge of the matter.
What markets does Numantec operate in?
Numantec operates manufacturing facilities across Europe and the United States, supplying healthcare products and drug-delivery devices.
When is the transaction expected to close?
The transaction is expected to be completed in the fourth quarter.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category